Shalin Kothari1, Jens Hillengass1, Philip L McCarthy1, Sarah A Holstein2. 1. Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 2. Department of Internal Medicine, University of Nebraska Medical Center, 986840 Nebraska Medical Center, Omaha, NE, 68198, USA. sarah.holstein@unmc.edu.
Abstract
PURPOSE OF REVIEW: The ability to detect minimal residual disease (MRD) in myeloma has improved due to advances in flow cytometry and sequencing methodologies. Here, we evaluate recent clinical trial data and explore the current and future roles of MRD assessment in the context of clinical trial design and clinical practice. RECENT FINDINGS: A review of recent phase III studies reveals that achievement of MRD negativity is associated with improved progression-free survival (PFS) and/or overall survival (OS). Treatment arms that are more effective from a PFS or overall response rate perspective are also associated with superior MRD negativity rates. The current standard MRD methodologies are limited by requiring bone marrow samples and refinement of methodologies that can detect disease outside of the bone marrow is needed. Currently, MRD is a prognostic biomarker and further efforts are required to determine whether it can serve as a surrogate endpoint. The use of MRD status to guide treatment decisions is currently not recommended outside the confines of a clinical trial.
PURPOSE OF REVIEW: The ability to detect minimal residual disease (MRD) in myeloma has improved due to advances in flow cytometry and sequencing methodologies. Here, we evaluate recent clinical trial data and explore the current and future roles of MRD assessment in the context of clinical trial design and clinical practice. RECENT FINDINGS: A review of recent phase III studies reveals that achievement of MRD negativity is associated with improved progression-free survival (PFS) and/or overall survival (OS). Treatment arms that are more effective from a PFS or overall response rate perspective are also associated with superior MRD negativity rates. The current standard MRD methodologies are limited by requiring bone marrow samples and refinement of methodologies that can detect disease outside of the bone marrow is needed. Currently, MRD is a prognostic biomarker and further efforts are required to determine whether it can serve as a surrogate endpoint. The use of MRD status to guide treatment decisions is currently not recommended outside the confines of a clinical trial.
Authors: Kenneth C Anderson; Daniel Auclair; Gary J Kelloff; Caroline C Sigman; Hervé Avet-Loiseau; Ann T Farrell; Nicole J Gormley; Shaji K Kumar; Ola Landgren; Nikhil C Munshi; Michele Cavo; Faith E Davies; Alessandra Di Bacco; Jennifer S Dickey; Steven I Gutman; Howard R Higley; Mohamad A Hussein; J Milburn Jessup; Ilan R Kirsch; Richard F Little; Robert D Loberg; Jens G Lohr; Lata Mukundan; James L Omel; Trevor J Pugh; Gregory H Reaman; Michael D Robbins; A Kate Sasser; Nancy Valente; Elena Zamagni Journal: Clin Cancer Res Date: 2017-04-20 Impact factor: 12.531
Authors: Mikhail Roshal; Juan A Flores-Montero; Qi Gao; Maesa Koeber; Jessica Wardrope; Brian G M Durie; Ahmet Dogan; Alberto Orfao; Ola Landgren Journal: Blood Adv Date: 2017-05-03
Authors: Juan Flores-Montero; Ruth de Tute; Bruno Paiva; José Juan Perez; Sebastian Böttcher; Henk Wind; Luzalba Sanoja; Noemí Puig; Quentin Lecrevisse; María Belén Vidriales; Jacques J M van Dongen; Alberto Orfao Journal: Cytometry B Clin Cytom Date: 2015-07-31 Impact factor: 3.058
Authors: David R Barnidge; Surendra Dasari; Chad M Botz; Danelle H Murray; Melissa R Snyder; Jerry A Katzmann; Angela Dispenzieri; David L Murray Journal: J Proteome Res Date: 2014-02-11 Impact factor: 4.466
Authors: Twyla B Bartel; Jeff Haessler; Tracy L Y Brown; John D Shaughnessy; Frits van Rhee; Elias Anaissie; Terri Alpe; Edgardo Angtuaco; Ronald Walker; Joshua Epstein; John Crowley; Bart Barlogie Journal: Blood Date: 2009-05-14 Impact factor: 22.113
Authors: Nina Shah; Jack Aiello; David E Avigan; Jesus G Berdeja; Ivan M Borrello; Ajai Chari; Adam D Cohen; Karthik Ganapathi; Lissa Gray; Damian Green; Amrita Krishnan; Yi Lin; Elisabet Manasanch; Nikhil C Munshi; Ajay K Nooka; Aaron P Rapoport; Eric L Smith; Ravi Vij; Madhav Dhodapkar Journal: J Immunother Cancer Date: 2020-07 Impact factor: 13.751